Clarke Lab

Research focus

NIH R01 · 2024

Neutral sphingomyelinase-2 as a mediator of Doxorubicin-induced cardiotoxicity

ABSTRACT Doxorubicin (Dox) is a mainstay in the treatment of many cancers yet its utility is limited by cardiovascular toxicity. While multiple mechanisms underlying this cardiotoxicity have been proposed, strategies targeting these pathways have had marginal effects or interfere with anti-cancer effects of the drug. Such concerns have restricted the clinical use of dexrazoxane which is currently the only FDA-approved cardio-protective agent. As cancer survival rates improve and more patients are exposed to Dox, there is a critical need for new strategies to mitigate the cardiotoxicity without comprising its therapeutic efficacy. Bioactive sphingolipids (SLs), especially ceramide (Cer), are…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.